bisantrene has been researched along with B16 Melanoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Citarella, RV; Durr, FE; Kohlbrenner, M; Lee, VJ; Murdock, KC; Nicolau, G | 1 |
1 other study(ies) available for bisantrene and B16 Melanoma
| Article | Year |
|---|---|
N-phosphoryl derivatives of bisantrene. Antitumor prodrugs with enhanced solubility and reduced potential for toxicity.
Topics: Animals; Anthracenes; Antibiotics, Antineoplastic; Leukemia P388; Melanoma, Experimental; Mice; Prodrugs; Rats; Rats, Sprague-Dawley | 1993 |